Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease

Adel R. Shehata, Alan W. Ahlberg, Linda Gillam, Victor A. Mascitelli, Jose M. Piriz, Rene A. Fleming, Chunguang Chen, David D. Waters, Gary V. Heller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Arbutamine, a new sympathomimetic compound, appears to elicit a more balanced inotropic and chronotropic response than dobutamine, currently used as a pharmacologic stress agent. The present study was performed to compare standard dobutamine stress testing with arbutamine for the detection of myocardial ischemia with technetium (Tc)-99m sestamibi tomographic imaging and 2-dimensional echocardiography in patients with coronary artery disease. Twenty-six patients with evidence of coronary artery disease underwent dobutamine infusion of 5 to 40 μg/kg/min in 3-minute stages. On a separate day, arbutamine was administered by an automated, computerized, closed-loop device monitoring bath heart rote and blood pressure. Both infusions were terminated upon achievement of target heart rate, completion of maximal infusion dose (dobutamine), heart rate saturation (arbutamine), or standard clinical end points. Tc-99m sestamibi was injected before termination of both infusions followed by tomographic myocardial perfusion imaging, whereas echocardiography was performed at baseline and throughout the infusions. There were no significant differences in maximal heart rate, blood pressure, and rate-pressure product as well as in the development of anginal symptoms or electrocardiographic changes during both infusions. The location and severity of myocardial perfusion defects and echocardiographic wall motion abnormalities were similar between both agents. It is concluded that arbutamine produces similar imaging results compared with standard dobutamine stress with both Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging and 2-dimensional echocardiography.

Original languageEnglish (US)
Pages (from-to)716-720
Number of pages5
JournalAmerican Journal of Cardiology
Volume80
Issue number6
DOIs
StatePublished - Sep 15 1997

Fingerprint

Myocardial Perfusion Imaging
Dobutamine
Echocardiography
Coronary Artery Disease
Technetium Tc 99m Sestamibi
Heart Rate
Blood Pressure
Sympathomimetics
Baths
Photons
Myocardial Ischemia
Perfusion
arbutamine
Pressure
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Shehata, Adel R. ; Ahlberg, Alan W. ; Gillam, Linda ; Mascitelli, Victor A. ; Piriz, Jose M. ; Fleming, Rene A. ; Chen, Chunguang ; Waters, David D. ; Heller, Gary V. / Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease. In: American Journal of Cardiology. 1997 ; Vol. 80, No. 6. pp. 716-720.
@article{b7b4fe8b8a2f4391ad25c2dfe5ca6f1f,
title = "Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease",
abstract = "Arbutamine, a new sympathomimetic compound, appears to elicit a more balanced inotropic and chronotropic response than dobutamine, currently used as a pharmacologic stress agent. The present study was performed to compare standard dobutamine stress testing with arbutamine for the detection of myocardial ischemia with technetium (Tc)-99m sestamibi tomographic imaging and 2-dimensional echocardiography in patients with coronary artery disease. Twenty-six patients with evidence of coronary artery disease underwent dobutamine infusion of 5 to 40 μg/kg/min in 3-minute stages. On a separate day, arbutamine was administered by an automated, computerized, closed-loop device monitoring bath heart rote and blood pressure. Both infusions were terminated upon achievement of target heart rate, completion of maximal infusion dose (dobutamine), heart rate saturation (arbutamine), or standard clinical end points. Tc-99m sestamibi was injected before termination of both infusions followed by tomographic myocardial perfusion imaging, whereas echocardiography was performed at baseline and throughout the infusions. There were no significant differences in maximal heart rate, blood pressure, and rate-pressure product as well as in the development of anginal symptoms or electrocardiographic changes during both infusions. The location and severity of myocardial perfusion defects and echocardiographic wall motion abnormalities were similar between both agents. It is concluded that arbutamine produces similar imaging results compared with standard dobutamine stress with both Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging and 2-dimensional echocardiography.",
author = "Shehata, {Adel R.} and Ahlberg, {Alan W.} and Linda Gillam and Mascitelli, {Victor A.} and Piriz, {Jose M.} and Fleming, {Rene A.} and Chunguang Chen and Waters, {David D.} and Heller, {Gary V.}",
year = "1997",
month = "9",
day = "15",
doi = "10.1016/S0002-9149(97)00501-8",
language = "English (US)",
volume = "80",
pages = "716--720",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease. / Shehata, Adel R.; Ahlberg, Alan W.; Gillam, Linda; Mascitelli, Victor A.; Piriz, Jose M.; Fleming, Rene A.; Chen, Chunguang; Waters, David D.; Heller, Gary V.

In: American Journal of Cardiology, Vol. 80, No. 6, 15.09.1997, p. 716-720.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease

AU - Shehata, Adel R.

AU - Ahlberg, Alan W.

AU - Gillam, Linda

AU - Mascitelli, Victor A.

AU - Piriz, Jose M.

AU - Fleming, Rene A.

AU - Chen, Chunguang

AU - Waters, David D.

AU - Heller, Gary V.

PY - 1997/9/15

Y1 - 1997/9/15

N2 - Arbutamine, a new sympathomimetic compound, appears to elicit a more balanced inotropic and chronotropic response than dobutamine, currently used as a pharmacologic stress agent. The present study was performed to compare standard dobutamine stress testing with arbutamine for the detection of myocardial ischemia with technetium (Tc)-99m sestamibi tomographic imaging and 2-dimensional echocardiography in patients with coronary artery disease. Twenty-six patients with evidence of coronary artery disease underwent dobutamine infusion of 5 to 40 μg/kg/min in 3-minute stages. On a separate day, arbutamine was administered by an automated, computerized, closed-loop device monitoring bath heart rote and blood pressure. Both infusions were terminated upon achievement of target heart rate, completion of maximal infusion dose (dobutamine), heart rate saturation (arbutamine), or standard clinical end points. Tc-99m sestamibi was injected before termination of both infusions followed by tomographic myocardial perfusion imaging, whereas echocardiography was performed at baseline and throughout the infusions. There were no significant differences in maximal heart rate, blood pressure, and rate-pressure product as well as in the development of anginal symptoms or electrocardiographic changes during both infusions. The location and severity of myocardial perfusion defects and echocardiographic wall motion abnormalities were similar between both agents. It is concluded that arbutamine produces similar imaging results compared with standard dobutamine stress with both Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging and 2-dimensional echocardiography.

AB - Arbutamine, a new sympathomimetic compound, appears to elicit a more balanced inotropic and chronotropic response than dobutamine, currently used as a pharmacologic stress agent. The present study was performed to compare standard dobutamine stress testing with arbutamine for the detection of myocardial ischemia with technetium (Tc)-99m sestamibi tomographic imaging and 2-dimensional echocardiography in patients with coronary artery disease. Twenty-six patients with evidence of coronary artery disease underwent dobutamine infusion of 5 to 40 μg/kg/min in 3-minute stages. On a separate day, arbutamine was administered by an automated, computerized, closed-loop device monitoring bath heart rote and blood pressure. Both infusions were terminated upon achievement of target heart rate, completion of maximal infusion dose (dobutamine), heart rate saturation (arbutamine), or standard clinical end points. Tc-99m sestamibi was injected before termination of both infusions followed by tomographic myocardial perfusion imaging, whereas echocardiography was performed at baseline and throughout the infusions. There were no significant differences in maximal heart rate, blood pressure, and rate-pressure product as well as in the development of anginal symptoms or electrocardiographic changes during both infusions. The location and severity of myocardial perfusion defects and echocardiographic wall motion abnormalities were similar between both agents. It is concluded that arbutamine produces similar imaging results compared with standard dobutamine stress with both Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging and 2-dimensional echocardiography.

UR - http://www.scopus.com/inward/record.url?scp=0031572275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031572275&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(97)00501-8

DO - 10.1016/S0002-9149(97)00501-8

M3 - Article

VL - 80

SP - 716

EP - 720

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -